Cost-effectiveness analysis for the parenteral anticoagulants in Jordan
S Alquraan, F Darwish El-Hajji - Journal of Pharmaceutical …, 2021 - academic.oup.com
Objectives Pharmacoeconomic dimensions linking clinical effectiveness of parenteral
anticoagulants for management of acute venous thromboembolism (VTE) and cost of …
anticoagulants for management of acute venous thromboembolism (VTE) and cost of …
[HTML][HTML] Études coût/efficacité: idées fausses et éléments de méthode
I Durand-Zaleski - Archives of Cardiovascular Diseases Supplements, 2016 - Elsevier
Résumé Les études coût/efficacité des traitements sont devenues pratique courante et
parfois obligatoires pour informer les décideurs publics sur l'impact économique des …
parfois obligatoires pour informer les décideurs publics sur l'impact économique des …
Anticoagulant plus antiplatelet therapy for atrial fibrillation
Background Emerging evidence indicates combination therapy with anticoagulants and
antiplatelet agents for atrial fibrillation (AF) will be increasingly required. Numerous studies …
antiplatelet agents for atrial fibrillation (AF) will be increasingly required. Numerous studies …
改良尿激酶静脉溶栓法治疗急性脑梗死的效果观察
尹耀慧， 黄书懿， 沈伟冰， 吕平华， 陆超， 林佳庆… - 中国当代医药, 2016 - cqvip.com
目的观察改良尿激酶静脉溶栓治疗急性脑梗死的临床效果及其安全性. 方法将我院2013 年1 月~
2014 年3 月收治的56 例发病在6 h 内的急性脑梗死患者随机分为传统尿激酶溶栓组(快速给药 …
2014 年3 月收治的56 例发病在6 h 内的急性脑梗死患者随机分为传统尿激酶溶栓组(快速给药 …
Le coût hospitalier des événements cérébro-vasculaires associés à une fibrillation atriale en France
G de Pouvourville, P Karam - Journal de gestion et d'économie de la santé, 2019 - cairn.info
Objectif: Les patients souffrant de fibrillation atriale sont à risque d'AVC ischémiques et
d'hémorragies cérébrales. L'objectif de cette étude était d'évaluer le coût hospitalier de ces …
d'hémorragies cérébrales. L'objectif de cette étude était d'évaluer le coût hospitalier de ces …
吲哚布芬与华法林用于非瓣膜性房颤患者抗凝治疗的药物经济学评价
唐密， 郑丽英， 韩晟 - 中国医疗保险, 2016 - cqvip.com
目的: 对中国非瓣膜性房颤患者使用吲哚布芬抗凝治疗进行药物经济学评价,
为中国房颤患者抗凝治疗药物的合理选用提供依据. 方法: 采用基于马尔可夫模型的成本效用 …
为中国房颤患者抗凝治疗药物的合理选用提供依据. 方法: 采用基于马尔可夫模型的成本效用 …
Imaginary Worlds: The Status of Modeled Quality Adjusted Life Year Claims for New Oral Anticoagulants in Atrial Fibrillation Published Between January 2012 and …
PC Langley, TG Rhee - INNOVATIONS in pharmacy, 2016 - pubs.lib.umn.edu
The purpose of this commentary is to evaluate modeled quality adjusted life year claims
(QALYs) for new oral anticoagulants (NOACs) published in the period from January 2012 to …
(QALYs) for new oral anticoagulants (NOACs) published in the period from January 2012 to …
[HTML][HTML] Cost-effectiveness of drug-eluting stents in elderly patients with coronary artery disease: the SENIOR trial
Background Elderly patients receive bare metal stents instead of drug-eluting stents (DES)
to shorten the duration of dual antiplatelet therapy (DAPT). The SENIOR trial compared …
to shorten the duration of dual antiplatelet therapy (DAPT). The SENIOR trial compared …
[HTML][HTML] Anticoagulant therapy for stroke prevention in people with atrial fibrillation
NGC UK - 2021 - ncbi.nlm.nih.gov
Atrial fibrillation (AF) is associated with a five-fold increase in the risk of thromboembolic
events (stroke/systemic embolism). When initiated in individuals at risk of a thromboembolic …
events (stroke/systemic embolism). When initiated in individuals at risk of a thromboembolic …
The Gap between economic evaluations and clinical practice: a systematic review of economic evaluations on dabigatran for atrial fibrillation
HJA Rolden, GJ van der Wilt, AHEM Maas… - International Journal of …, 2018 - cambridge.org
Objectives: As model-based economic evaluations (MBEEs) are widely used to make
decisions in the context of policy, it is imperative that they represent clinical practice. Here …
decisions in the context of policy, it is imperative that they represent clinical practice. Here …